Veri Medtech Holdings, Inc. Announces 1-for-2.5 Reverse Stock Split
NEW YORK, N.Y., September 1, 2026 (OTC MARKETS) — Veri Medtech Holdings, Inc. (OTC Markets: VRHI) (“Veri Medtech” or the “Company”), a healthcare technology company, today announced that its Board of Directors has approved a 1-for-2.5 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).
The Company continues to pursue its pending application for an uplisting to a national securities exchange. There can be no assurance that the application will be approved or that the Company will satisfy all applicable listing requirements. Additional information regarding the Company is available in the Company’s Amended Registration Statement on Form S-1.
The Reverse Stock Split will become effective on September 2, 2026, at 12:01 a.m. Eastern Time. FINRA has processed the corporate action related to the Reverse Stock Split.
Following the Reverse Stock Split, the Company’s Common Stock will begin trading on a split-adjusted basis on OTC Markets under the temporary ticker symbol “VRHID.” The temporary “D” suffix will remain for 20 business days following the Reverse Stock Split, after which the Company’s trading symbol will revert to “VRHI.”
The new CUSIP number for the Company’s Common Stock following the Reverse Stock Split will be 53223L301.
Under the terms of the Reverse Stock Split, every 2.5 shares of the Company’s Common Stock issued and outstanding immediately prior to the effective time will automatically be combined and converted into one share of Common Stock.
The Company currently has approximately 20,000,003 shares of Common Stock issued and outstanding. Following the Reverse Stock Split, the Company will have approximately 8,000,004 shares of Common Stock issued and outstanding, subject to the treatment of fractional shares described below.
The Reverse Stock Split will not change the par value of the Company’s Common Stock, which will remain $0.0001 per share, and will not change the Company’s authorized number of shares of Common Stock or preferred stock.
No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders of record who otherwise would be entitled to receive a fractional share as a result of the Reverse Stock Split will automatically receive an additional fraction of a share sufficient to round up to the next whole share.
With respect to shares of Common Stock held in “street name” through a bank, broker, or other nominee, fractional shares will be rounded up at the participant level. No cash will be paid in lieu of fractional shares.
About Veri Medtech Holdings, Inc.:
Veri Medtech Holdings, Inc. (OTC Markets: VRHI) is a publicly traded healthcare technology company focused on alternative medicine, personalized diagnostics, and on-demand wellness services. The Company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to support accessible and personalized healthcare. Veri Medtech also evaluates strategic acquisitions and other opportunities that complement its core capabilities and expand its presence across alternative medicine, longevity, and wellness. For more information, please visit www.VeriMedTech.com.
Company Information:
The information provided on the Company's website, in its press releases, related materials, and in any documents or communications distributed by Veri Medtech Holdings, Inc. (the "Company") is for informational purposes only. Company information does not constitute an offer or solicitation to sell shares or securities in the Company or any related or associated entity. Any such offer or solicitation will be made solely through a Company offering memorandum or similar formal investment documentation and in accordance with all applicable securities laws and regulations. No information, statements, or analyses presented on the Company's website, in Company media, press releases, or other Company materials are intended to form the basis of any investment decision, nor do they constitute investment advice, recommendations, or counsel. This material does not constitute or form part of, and should not be construed as, any offer for sale or subscription, or any invitation to offer to buy or subscribe for any securities. No portion of this material should form the basis of, or be relied upon in connection with, any contract or commitment of any kind. The Company expressly disclaims any and all liability for any direct or consequential loss or damage arising directly or indirectly from: (i) reliance on any information provided herein or in related materials; (ii) any error, omission, or inaccuracy in such information; or (iii) any action taken or decision made based on such information.
Forward-Looking Statements:
Cautionary Note Regarding Forward-Looking Statements: This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the Company's business strategy, growth opportunities, acquisitions, operations, and future prospects. Forward-looking statements are based on current expectations, estimates, assumptions, and projections and are subject to risks and uncertainties. Such statements are not guarantees of future performance, and actual results may differ materially from those expressed or implied by these forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, except as may be required by applicable laws.